Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | 1816.00 | 58.17 Thousand | 63.2 Thousand | 66.08 Thousand |
| Gross Profit | - | - | -1816.00 | -58.17 Thousand | -63.2 Thousand | -66.08 Thousand |
| Operating Expenses | - | - | 1.26 Million | 837 Thousand | 1.16 Million | 2.12 Million |
| Selling, General and Administrative Expenses | - | - | 1.04 Million | 593.54 Thousand | 907.83 Thousand | 1.78 Million |
| Research and Development Expenses | - | - | 217.58 Thousand | 243.45 Thousand | 255.39 Thousand | 344.97 Thousand |
| Other Expenses | - | - | - | 1.65 Million | - | - |
| Cost and Expenses | - | - | 1.26 Million | 837 Thousand | 1.16 Million | 2.12 Million |
| Operating Income | - | - | -1.26 Million | -837 Thousand | -513.23 Thousand | -2.07 Million |
| Interest Expense | - | - | 57.4 Thousand | 43.78 Thousand | 39.51 Thousand | 20.21 Thousand |
| Income Tax Expense | - | - | -76.25 Thousand | -43.76 Thousand | -767.86 Thousand | -252.36 Thousand |
| Earnings before Tax | - | - | -651.55 Thousand | 779.12 Thousand | -552.74 Thousand | -2.09 Million |
| Net Income | - | - | -575.29 Thousand | 866.67 Thousand | -434.88 Thousand | -1.89 Million |
| Earnings Per Share Basic | - | - | -0.02 | 0.06 | -0.03 | -0.13 |
| Earnings Per Share Diluted | - | - | -0.02 | 0.06 | -0.03 | -0.13 |
| Weighted Average Shares Outstanding | - | - | 24.11 Million | 14.48 Million | 14.41 Million | 14.29 Million |
| Weighted Average Shares Outstanding (Diluted) | - | - | 24.11 Million | 14.48 Million | 14.41 Million | 14.29 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | -1.26 Million | -778.82 Thousand | -450.02 Thousand | -2.06 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2022 FY | 2021 FY | 2020 FY | 2020 Q4 | 2020 Q3 | 2020 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | 1816.00 | - | - | - |
| Gross Profit | - | - | -1816.00 | - | - | - |
| Operating Expenses | - | - | 1.26 Million | 477.94 Thousand | 388.69 Thousand | 242.65 Thousand |
| Selling, General and Administrative Expenses | - | - | - | 422.2 Thousand | 322.58 Thousand | 193.53 Thousand |
| Research and Development Expenses | - | - | - | 55.74 Thousand | 66.11 Thousand | 49.12 Thousand |
| Other Expenses | - | - | - | - | - | 66.75 Thousand |
| Cost and Expenses | - | - | 1.26 Million | 477.94 Thousand | 388.69 Thousand | 242.65 Thousand |
| Operating Income | - | - | -1.26 Million | -1.07 Million | -388.69 Thousand | 357.34 Thousand |
| Interest Expense | - | - | 57.4 Thousand | 12.84 Thousand | 12.7 Thousand | 15.91 Thousand |
| Income Tax Expense | - | - | -76.25 Thousand | -33.87 Thousand | -27.56 Thousand | -11.69 Thousand |
| Earnings before Tax | - | - | -651.55 Thousand | -489.5 Thousand | -401.4 Thousand | 408.17 Thousand |
| Net Income | - | - | -575.29 Thousand | -455.63 Thousand | -373.83 Thousand | 435.78 Thousand |
| Earnings Per Share Basic | - | - | - | -0.02 | -0.02 | 0.03 |
| Earnings Per Share Diluted | - | - | - | -0.02 | -0.02 | 0.00 |
| Weighted Average Shares Outstanding | - | - | 24.11 Million | 24.11 Million | 24.44 Million | 15.02 Million |
| Weighted Average Shares Outstanding (Diluted) | - | - | 24.11 Million | 24.11 Million | 24.44 Million | 102.35 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | - | -477.28 Thousand | -388.32 Thousand | -242.28 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
BYD
MUX
AILLM
HBGRF
002017
HIPH